|
Oxford BioMedica PLC announced on Monday it had exchanged contracts for the sale and leaseback of its Windrush Court facility to Kadans Science Partner for £60 million.
Kadans have granted the Oxfordshire, England-based gene and cell therapy group a 15-year occupational lease at a rent of £3.5 million per year, rising to £4.7 million after five years and subject to a market rent review after 10 years.
The sale proceeds exceeded Oxford BioMedica's target of £55 million, allowing its cash position to strengthen to more than £150 million. The net book value of the Windrush Court facility was £7.9 million.
"The proceeds of the transaction will enhance our net cash position, providing us with additional financial flexibility as we build our leadership as an innovation-led [contract development and manufacturing organisation] across all viral vectors for cell and gene therapy," said Stuart Paynter, Chief Financial Officer of Oxford BioMedica.
The Windrush court facility consists of around 75,000 square feet of office space, including state-of-the-art laboratories. It currently houses Oxford BioMedica's analytical services group and process research and development functions.
Shares in Oxford BioMedica were up 1.7% to 332.50 pence in London on Monday afternoon.
The sale is due to complete on Friday.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
